<DOC>
	<DOC>NCT00146822</DOC>
	<brief_summary>The REFLEx Study will evaluate if ENDOTAK RELIANCE G defibrillation leads with GORE ePTFE-covered coils are as good as or better than other comparative commercially available defibrillation leads with respect to electrical performance and termination efficacy in spontaneous tachyarrhythmic episodes.</brief_summary>
	<brief_title>REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance</brief_title>
	<detailed_description />
	<criteria>Patients who meet current ICD or CRTD indications Patients who are going to be implanted with one of the aforementioned ICD or CRTD devices Patients who are going to be implanted with activefixation, dualcoil, endocardial defibrillation leads with compatible connectors (i.e., ENDOTAK RELIANCE G or studycomparative ICD leads) Patients who sign and date a Patient Informed Consent form prior to device implant Patients who remain in the clinical care of the enrolling physician in approved centers Patients who are at least 18 years old Patients who have a preexisting transvenous lead system that is not completely explanted Patients who are hypersensitive to a single dose of approximately 1.0 mg of dexamethasone acetate Patients who are expected to receive a heart transplant during the duration of the study Patients whose estimated life expectancy is less than 12 months due to other medical conditions Patients who currently have or who are likely to receive a tricuspid valve prosthesis Patients who are likely to have an openchest surgery in the next three months Patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the REFLEx study. Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study Patients who are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>